DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism

Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used incretin-based therapy for the treatment of type 2 diabetes. We investigated the cardioprotective effect of a DPP-4 inhibitor, vildagliptin ( vilda ), on myocardial metabolism and cardiac performance under pressure overload. Mice were treated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Heart and vessels 2021-01, Vol.36 (1), p.136-146
Hauptverfasser:	Furukawa, Nozomi, Koitabashi, Norimichi, Matsui, Hiroki, Sunaga, Hiroaki, Umbarawan, Yogi, Syamsunarno, Mas Rizky A. A., Yamaguchi, Aiko, Obokata, Masaru, Hanaoka, Hirofumi, Yokoyama, Tomoyuki, Kurabayashi, Masahiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Aorta Biomedical Engineering and Bioengineering Cardiac Surgery Cardiology Cardiomyocytes Diabetes mellitus (non-insulin dependent) Dipeptidyl-peptidase IV Energy metabolism Energy resources Fatty acids Fibroblast growth factors Fibroblasts Growth factors Heart Hypertrophy Medicine Medicine & Public Health Metabolism Muscle contraction Original Original Article Overloading Peptidase Peptidases Pressure SIRT1 protein Substrates Vascular Surgery Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!